Biocon, Asia's premier biopharmaceutical company, has received regulatory approval for its biosimilar Insulin Glargine from the Ministry of Health, Labour and Welfare (MHLW) of Japan. This is a significant achievement for the company and its commercial partner, FUJIFILM Pharma (FFP) as it endorses endeavor to bring high quality, yet affordable, world class products to diabetes patients in Japan.
The product is a ready-to-use, prefilled disposable pen with 3 ml of 100IU Insulin Glargine, expected to be launched in Q1 FY17, aiming to capture a significant share of the Japanese Glargine market of $144 million, which is the second largest market outside of North America & Europe and is largely dominated by disposable pens.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
